| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 1 | 枯草杆菌酶变体和编码它们的多核苷酸 | CN201280063467.X | 2012-12-18 | CN104011204A | 2014-08-27 | W.贝森马特; A.本尼; E.P.弗里斯; P.O.米奇尔森 |
| 本发明涉及多种蛋白酶变体以及用于获得蛋白酶变体的多种方法。本发明还涉及编码这些变体的多核苷酸；包含这些多核苷酸的核酸构建体、载体、以及宿主细胞；以及使用这些变体的方法。 | ||||||
| 2 | TOBACCO PROTEASE GENES | US15325997 | 2015-07-16 | US20170265516A1 | 2017-09-21 | Lucien Bovet; Dion Florack; James Battey |
| The invention provides protease genes which are regulated in a specific manner during curing of tobacco plants material and which affect the flavour of cured tobacco. | ||||||
| 3 | INHIBITION OF PCSK9 THROUGH RNAI | US15286948 | 2016-10-06 | US20170137823A1 | 2017-05-18 | Joanne Kamens; Anastasia Khvorova |
| The invention relates to various PCSK9 RNAi constructs with gene silencing activities, and uses thereof. The construct has a double-stranded region of 19-49 nucleotides, preferably 25, 26, or 27 nucleotides, and preferably blunt-ended. The construct has selective minimal modifications to confer an optimal balance of biological activity, toxicity, stability, and target gene specificity. The sense strand may be modified such that the construct is not cleaved by Dicer or other RNAse III, and the entire length of the antisense strand is loaded into RISC In addition, the antisense strand may also be modified by 2′-O-methyl groups at the 2nd 5′-end nucleotide to greatly reduce off-target silencing. The constructs of the invention largely avoid the interferon response and sequence-independent apoptosis in mammalian cells, exhibits better serum stability, and enhanced target specificity. | ||||||
| 4 | Treatment of membrane bound transcription factor peptidase, site 1 (MBTPS1) related diseases by inhibition of natural antisense transcript to MBTPS1 | US13516097 | 2010-12-15 | US09173895B2 | 2015-11-03 | Joseph Collard; Olga Khorkova Sherman |
| The present invention relates to antisense oligonuclotides that modulate the expression of and/or function of Membrane Bound Transcription Factor Peptidase, site 1 (MBTPS1), in particular, by targeting natural antisense polynucleotides of Membrane Bound Transcription Factor Peptidase, site 1 (MBTPS1). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of MBTPS1. | ||||||
| 5 | rna antagonist compounds for modulating the Pcsk9 | JP2009531824 | 2007-10-09 | JP2010505432A | 2010-02-25 | エレン・マリー・ストラールップ; ニルス・フィスケル・ニルセン |
| 本発明は、PCSK9の発現を調節する化合物、組成物および方法を提供する。 特に、本発明は、PCSK9をコードする標的核酸とハイブリダイズ可能なオリゴマー化合物、例えばオリゴヌクレオチド化合物、および、かかるオリゴマー化合物を調製する方法に関する。 本オリゴヌクレオチド化合物がPCSK9の発現を調節することを示し、またそれらの医薬、ならびに高コレステロール血症および関連障害の処置におけるそれらの使用を開示する。 | ||||||
| 6 | Treatment of mbtps1-related diseases due to the inhibition of membrane-bound transcription factor peptidase, natural antisense transcript to the site 1 (mbtps1) | JP2012544744 | 2010-12-15 | JP2013515459A | 2013-05-09 | コラード，ジョセフ; シャーマン，オルガ コルコヴァ |
| 本発明は、特に、膜結合転写因子ペプチダーゼ、部位１（ＭＢＴＰＳ１）の天然アンチセンスポリヌクレオチドを標的にすることによって膜結合転写因子ペプチダーゼ、部位１（ＭＢＴＰＳ１）ポリヌクレオチドの発現および／または機能を調節するアンチセンスオリゴヌクレオチドに関する。 本発明はまた、上記アンチセンスオリゴヌクレオチドの同定およびＭＢＴＰＳ１の発現に関連する疾患または傷害の治療におけるその使用にも関する。
【選択図】図１ |
||||||
| 7 | RNA ANTAGONIST COMPOUNDS FOR THE MODULATION OF PCSK9 | EP07821072.1 | 2007-10-09 | EP2076597A2 | 2009-07-08 | STRAARUP, Ellen Marie; NIELSEN, Niels Fisher |
| The present invention provides compounds, compositions and methods for modulating the expression of PCSK9. In particular, this invention relates to oligomeric compounds, such as oligonucleotide compounds, which are hybridisable with target nucleic acids encoding PCSK9, and methods for the preparation of such oligomeric compounds. The oligonucleotide compounds have been shown to modulate the expression of PCSK9, and pharmaceutical preparations thereof and their use as treatment of hypercholesterolemia and related disorders are disclosed. | ||||||
| 8 | Treatment of membrane bound transcription factor peptidase, site 1 (MBTPS1) related diseases by inhibition of natural antisense transcript to MBTPS1 | US14857259 | 2015-09-17 | US09879264B2 | 2018-01-30 | Joseph Collard; Olga Khorkova Sherman |
| The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Membrane Bound Transcription Factor Peptidase, site 1 (MBTPS1), in particular, by targeting natural antisense polynucleotides of Membrane Bound Transcription Factor Peptidase, site 1 (MBTPS1). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of MBTPS1. | ||||||
| 9 | Inhibition of PCSK9 through RNAi | US13143275 | 2010-01-05 | US09493774B2 | 2016-11-15 | Joanne Kamens; Anastasia Khvorova |
| The invention relates to various PCSK9 RNAi constructs with gene silencing activities, and uses thereof. The construct has a double-stranded region of 19-49 nucleotides, preferably 25, 26, or 27 nucleotides, and preferably blunt-ended. The construct has selective minimal modifications to confer an optimal balance of biological activity, toxicity, stability, and target gene specificity. The sense strand may be modified such that the construct is not cleaved by Dicer or other RNAse III, and the entire length of the antisense strand is loaded into RISC. In addition, the antisense strand may also be modified by 2′-O-methyl groups at the 2nd 5′-end nucleotide to greatly reduce off-target silencing. The constructs of the invention largely avoid the interferon response and sequence-independent apoptosis in mammalian cells, exhibits better serum stability, and enhanced target specificity. | ||||||
| 10 | SUBTILASE VARIANTS AND POLYNUCLEOTIDES ENCODING SAME | US15016884 | 2016-02-05 | US20160152962A1 | 2016-06-02 | Werner Besenmatter; Astrid Benie; Esben Peter Friis; Pernille Ollendorf Micheelsen |
| The present invention relates to protease variants and methods for obtaining protease variants. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants. | ||||||
| 11 | TREATMENT OF MEMBRANE BOUND TRANSCRIPTION FACTOR PEPTIDASE, SITE 1 (MBTPS1) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO MBTPS1 | EP10842521.6 | 2010-12-15 | EP2513310A2 | 2012-10-24 | COLLARD, Joseph; KHORKOVA SHERMAN, Olga |
| The present invention relates to antisense oligonuclotides that modulate the expression of and/or function of Membrane Bound Transcription Factor Peptidase, site 1 (MBTPS1), in particular, by targeting natural antisense polynucleotides of Membrane Bound Transcription Factor Peptidase, site 1 (MBTPS1). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of MBTPS1. | ||||||
| 12 | たばこプロテアーゼ遺伝子 | JP2017502853 | 2015-07-16 | JP2017529063A | 2017-10-05 | リュシアン ボベット; ディオン フローラック; ジェームズ バティ |
| 本発明は、たばこ植物材料の乾燥処理間に特異的な方法で調節され、かつ乾燥処理したたばこの風味に影響する、プロテアーゼ遺伝子を提供する。【選択図】なし | ||||||
| 13 | 膜結合転写因子ペプチダーゼ、部位1(MBTPS1)に対する天然アンチセンス転写物の阻害によるMBTPS1関連性疾患の治療 | JP2012544744 | 2010-12-15 | JP6025567B2 | 2016-11-16 | コラード,ジョセフ; コルコヴァ シャーマン,オルガ |
| 14 | サブチラーゼ変異体およびそれをコードするポリヌクレオチド | JP2014547944 | 2012-12-18 | JP2015504660A | 2015-02-16 | ベゼンマッター ベルナー; ベニー アストリド; ペテル フリイス エスベン; オレンドルフ ミケールセン ペルニーレ |
| 本発明は、プロテアーゼ変異体およびプロテアーゼ変異体を得るための方法に関する。本発明はまた、この変異体をコードするポリヌクレオチド;このポリヌクレオチドを含む核酸構築物、ベクターおよび宿主細胞;ならびにこの変異体を用いる方法に関する。 | ||||||
| 15 | INHIBITION OF PCSK9 THROUGH RNAI | US16191396 | 2018-11-14 | US20190218557A1 | 2019-07-18 | Joanne Kamens; Anastasia Khvorova |
| The invention relates to various PCSK9 RNAi constructs with gene silencing activities, and uses thereof. The construct has a double-stranded region of 19-49 nucleotides, preferably 25, 26, or 27 nucleotides, and preferably blunt-ended. The construct has selective minimal modifications to confer an optimal balance of biological activity, toxicity, stability, and target gene specificity. The sense strand may be modified such that the construct is not cleaved by Dicer or other RNAse III, and the entire length of the antisense strand is loaded into RISC In addition, the antisense strand may also be modified by 2′-O-methyl groups at the 2nd 5′-end nucleotide to greatly reduce off-target silencing. The constructs of the invention largely avoid the interferon response and sequence-independent apoptosis in mammalian cells, exhibits better serum stability, and enhanced target specificity. | ||||||
| 16 | SUBTILASE VARIANTS AND POLYNUCLEOTIDES ENCODING SAME | US15992386 | 2018-05-30 | US20180265855A1 | 2018-09-20 | Werner Besenmatter; Astrid Benie; Esben Peter Friis; Pernille Ollendorf Micheelsen |
| The present invention relates to protease variants and methods for obtaining protease variants. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants. | ||||||
| 17 | TREATMENT OF MEMBRANE BOUND TRANSCRIPTION FACTOR PEPTIDASE, SITE 1 (MBTPS1) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO MBTPS1 | US14857259 | 2015-09-17 | US20160002640A1 | 2016-01-07 | Joseph COLLARD; Olga Khorkova Sherman |
| The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Membrane Bound Transcription Factor Peptidase, site 1 (MBTPS1), in particular, by targeting natural antisense polynucleotides of Membrane Bound Transcription Factor Peptidase, site 1 (MBTPS1). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of MBTPS1. | ||||||
| 18 | Subtilase Variants and Polynucleotides Encoding Same | US14364191 | 2012-12-18 | US20140335596A1 | 2014-11-13 | Werner Besenmatter; Astrid Benie; Esben Peter Friis; Pernille Ollendorf Micheelsen |
| The present invention relates to protease variants and methods for obtaining protease variants. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants. | ||||||
| 19 | INHIBITION OF PCSK9 THROUGH RNAI | US13143275 | 2010-01-05 | US20130197055A1 | 2013-08-01 | Joanne Kamens; Anastasia Khvorova |
| The invention relates to various PCSK9 RNAi constructs with gene silencing activities, and uses thereof The construct has a double-stranded region of 19-49 nucleotides, preferably 25, 26, or 27 nucleotides, and preferably blunt-ended The construct has selective minimal modifications to confer an optimal balance of biological activity, toxicity, stability, and target gene specificity The sense strand may be modified such that the construct is not cleaved by Dicer or other RNAse III, and the entire length of the antisense strand is loaded into RISC In addition, the antisense strand may also be modified by 2′-O-methyl groups at the 2nd 5′-end nucleotide to greatly reduce off-target silencing The constructs of the invention largely avoid the interferon response and sequence-independent apoptosis in mammalian cells, exhibits better serum stability, and enhanced target specificity. | ||||||
| 20 | TREATMENT OF MEMBRANE BOUND TRANSCRIPTION FACTOR PEPTIDASE, SITE 1 (MBTPS1) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO MBTPS1 | US13516097 | 2010-12-15 | US20130116300A1 | 2013-05-09 | Joseph Collard; Olga Khorkova Sherman |
| The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Membrane Bound Transcription Factor Peptidase, site 1 (MBTPS1), in particular, by targeting natural antisense polynucleotides of Membrane Bound Transcription Factor Peptidase, site 1 (MBTP-S1). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of MBTPS1. | ||||||
QQ群二维码
意见反馈
意见反馈